



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 13:00
Last Report Issued 09/13/2011 08:13

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 3157U-POS
Patient ID 3157U-POS
Chain 11002014
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 11002014
Received 09/13/2011 08:06

Sample ID 11002014-001
Matrix Urine
Patient Name 3157U-POS
Patient ID 3157U-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
3157U Cotinine and Anabasine from Secondary Exposure, Urine				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Cotinine	5.0	ng/mL	1.0	
Synonym(s): Nicotine Metabolite				
Reported urine Cotinine concentrations: <5 ng/mL in non-smokers with no secondary smoke exposure, 5 - 50 ng/mL in non-smokers with secondary exposure to smoke, <50 ng/mL in abstinent smokers following a 2 week abstinence.				
Anabasine	5.0	ng/mL	1.0	
The presence of anabasine in urine is consistent with tobacco product use. Anabasine concentrations in the urine of tobacco users are much lower than cotinine concentrations. Anabasine is not present in nicotine replacement therapy products such as transdermal patches, gum, nasal sprays and inhalers.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.